A phase III study found a combination therapy to reduce the risk of progression-free survival as an initial treatment for certain patients with advanced kidney cancer.

News

A phase III study found a combination therapy to reduce the risk of progression-free survival as an initial treatment for certain patients with advanced kidney cancer.
A recent study examined the effect of medication nonadherence on progression-free survival among patients with renal cell carcinoma.
Intravesical installation with gemcitabine following transurethral resection of bladder tumor is associated with a reduced recurrence rate of non-muscle invasive bladder cancer in patients with low-grade disease.
In a recent study, researchers compared the effectiveness of chemotherapy plus radiotherapy vs chemotherapy alone in patients with locally advanced bladder cancer.

Research in Review

Stereotactic ablative radiation therapy can achieve more than 90% control of renal cell carcinoma metastases, according to a study published in the International Journal of Radiation Oncology, Biology, and Physics (May 1, 2017;98[1]:91-100).

-----

Related Content

Read More

Patients with renal cell carcinoma who have surgery to remove metastatic tumors are likely to double their life expectancy, according to research published in The Journal of Urology (April 2017;197[4]:e954).

-----

Related Content

Read More

Primary non-small cell lung cancer (NSCLC) may be underdiagnosed in patients with metastatic renal cell carcinoma, according to new research.

-----

Related Content

Read More

First-line therapy with cabozantinib was superior to standard of care sunitinib with respect to progression-free survival and objective response rate for patients with intermediate- or poor-risk metastatic renal cell carcinoma (mRCC), according to a study published in the Journal of Clinical Oncology.

-----

Related Content

Read More

Subscribe to Kidney Cancer